Comparing the Efficacy of Cyclooxygenase 2-Specific Inhibitors in Treating Osteoarthritis: Appropriate Trial Design Considerations and Results of a Randomized, Placebo-Controlled Trial

Arthritis and Rheumatism

Volumn 48, Issue 11, 2003, Pages 3102-3111

  Gibofsky, Allan ^a   Williams, Gary W ^b   McKenna, Frank ^c   Fort, John G ^d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b SCRIPPS CLINIC   (United States)

^c TRAFFORD GENERAL HOSPITAL   (United Kingdom)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; PARACETAMOL; PLACEBO; ROFECOXIB;

ABDOMINAL PAIN; ACCIDENT; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BRONCHOSPASM; CLINICAL FEATURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENDOMETRIUM TUMOR; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; LEG CRAMP; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEOPLASM; OSTEOARTHRITIS; PAIN ASSESSMENT; PATIENT SATISFACTION; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; SINUSITIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE;

CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; OSTEOARTHRITIS; PAIN MEASUREMENT; PYRAZOLES; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; SULFONES; TREATMENT OUTCOME;

EID: 0242552926     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11330     Document Type: Article

References (24)

1. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43:1905-15.
2. American Pain Society. Guideline for the management of pain in osteoarthritis, rheumatoid arthritis and juvenile chronic arthritis. Glenview, IL: American Pain Society; 2002.
3. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized, controlled trial. Mayo Clin Proc 1999;74:1095-105.
4. Williams GW, Ettlinger RE, Ruderman EM, Hubbard RC, Lonien ME, Yu SS, et al. Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial. J Clin Rheumatol 2000;6:65-74.
5. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee: a placebo-controlled, randomised, double-blind comparison. Scand J Rheumatol 2001;30:11-8.
6. Saag K, van der Heijde D, Fisher C, Samara C, DeTora L, Bolognese J, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Arch Fam Med 2000;9:1124-34.
7. Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160:1781-7.
8. Truitt KE, Sperling RS, Ettinger WH Jr, Greenwald M, DeTora L, Zeng O, et al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging (Milano) 2001;13:112-21.
9. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921-8.
10. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized, controlled trial. JAMA 2000;284:1247-55.
11. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;117:776-83.
12. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
13. McKenna F, Weaver A, Fiechtner JJ, Bello AE, Fort JG. COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study. J Clin Rheumatol 2001;7:151-9.
14. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002;287:64-71.
15. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
16. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
17. American Rheumatism Association Glossary Committee. Dictionary of the rheumatic diseases: signs and symptoms. Vol. 1. New York: Contact Associates International; 1988.
18. Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee: validation-value in comparison with other assessment tests. Scand J Rheumatol Suppl 1987;65:85-9.
19. Bellamy N. WOMAC osteoarthritis index: a user's guide. London (Ontario): The Western Ontario and McMaster Universities; 1995.
20. Emery P, Kong SX, Ehrich EW, Watson DJ, Towheed TE. Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature review. Clin Ther 2002;24:1225-91.
21. Makarowski W, Zhao WW, Bevirt T, Recker DP. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002;10:290-6.
22. Bellamy N, Carr A, Dougados M, Shea B, Wells G. Towards a definition of "difference" in osteoarthritis. J Rheumatol 2001;28:427-30.
23. Ehrich EW, Davies GM, Watson DJ, Bolognese JA, Steinberg BC, Bellamy N, et al. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol 2000;27:2635-41.
24. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: statistical principles for clinical trials. February 1998.